Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 1
2010 1
2011 4
2012 2
2013 2
2014 3
2015 5
2016 2
2017 2
2018 1
2019 2
2021 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH).
Brennan PN, MacMillan M, Manship T, Moroni F, Glover A, Graham C, Semple S, Morris DM, Fraser AR, Pass C, McGowan NWA, Turner ML, Lachlan N, Dillon JF, Campbell JDM, Fallowfield JA, Forbes SJ. Brennan PN, et al. BMJ Open. 2021 Nov 8;11(11):e053190. doi: 10.1136/bmjopen-2021-053190. BMJ Open. 2021. PMID: 34750149 Free PMC article.
Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study.
Grecian SM, McLachlan S, Fallowfield JA, Hayes PC, Guha IN, Morling JR, Glancy S, Williamson RM, Reynolds RM, Frier BM, Zammitt NN, Price JF, Strachan MWJ. Grecian SM, et al. Obes Sci Pract. 2021 May 6;7(5):497-508. doi: 10.1002/osp4.484. eCollection 2021 Oct. Obes Sci Pract. 2021. PMID: 34631129 Free PMC article.
Emerging synthetic drugs for the treatment of liver cirrhosis.
Fallowfield JA, Jimenez-Ramos M, Robertson A. Fallowfield JA, et al. Expert Opin Emerg Drugs. 2021 Jun;26(2):149-163. doi: 10.1080/14728214.2021.1918099. Epub 2021 Apr 26. Expert Opin Emerg Drugs. 2021. PMID: 33856246 Review.
A relaxin-based nanotherapy for liver fibrosis.
Fallowfield JA, Ramachandran P. Fallowfield JA, et al. Nat Nanotechnol. 2021 Apr;16(4):365-366. doi: 10.1038/s41565-020-00832-w. Nat Nanotechnol. 2021. PMID: 33495619 No abstract available.
Resolving the fibrotic niche of human liver cirrhosis at single-cell level.
Ramachandran P, Dobie R, Wilson-Kanamori JR, Dora EF, Henderson BEP, Luu NT, Portman JR, Matchett KP, Brice M, Marwick JA, Taylor RS, Efremova M, Vento-Tormo R, Carragher NO, Kendall TJ, Fallowfield JA, Harrison EM, Mole DJ, Wigmore SJ, Newsome PN, Weston CJ, Iredale JP, Tacke F, Pollard JW, Ponting CP, Marioni JC, Teichmann SA, Henderson NC. Ramachandran P, et al. Nature. 2019 Nov;575(7783):512-518. doi: 10.1038/s41586-019-1631-3. Epub 2019 Oct 9. Nature. 2019. PMID: 31597160 Free PMC article.
Safety profile of autologous macrophage therapy for liver cirrhosis.
Moroni F, Dwyer BJ, Graham C, Pass C, Bailey L, Ritchie L, Mitchell D, Glover A, Laurie A, Doig S, Hargreaves E, Fraser AR, Turner ML, Campbell JDM, McGowan NWA, Barry J, Moore JK, Hayes PC, Leeming DJ, Nielsen MJ, Musa K, Fallowfield JA, Forbes SJ. Moroni F, et al. Nat Med. 2019 Oct;25(10):1560-1565. doi: 10.1038/s41591-019-0599-8. Epub 2019 Oct 7. Nat Med. 2019. PMID: 31591593 Clinical Trial.
27 results